EUVIMEDDescoperă EUVIMED
Crossref

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes

Yichen Yan, Ruitao Lin iD, Tianyu Guan, Haolun Shi iD, Xiaolei Lin iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70049 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Yichen Yan and 4 co-authors. Institution: Department of Statistical and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada. Major MEDLINE topics: Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Dose-Response Relationship, Drug, Research Design. 36 references. Funded by: National Natural Science Foundation of China, Natural Sciences and Engineering Research Council of Canada, Canadian Statistical Sciences Institute (CANSSI).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Pursuing accurate observations and rational assumptions always drives advances in clinical trial design. In recent years, more trials have begun to collect multi‐graded outcomes for more informative analyses. At the same time, assumptions other than the traditional monotonicity relationship have been considered in the dose‐efficacy curve to be more realistic. Inspired by these two trends, we propose a phase I/II design that simultaneously considers multi‐categorical toxicity and efficacy with multi‐graded outcomes, measured as quasi‐continuous probability based on prespecified weight matrices of clinical significance. Following keyboard design, our approach aims to screen out overly toxic doses by the toxicity probability intervals and adaptively makes dose escalation or de‐escalation decisions by comparing the posterior distributions of dose desirability (utility) among the adjacent levels of the current dose. It helps to more accurately identify the OBD in a non‐monotonically increasing dose‐efficacy relationship. We also comprehensively present the safety, accuracy and reliability performance through numerical simulations in multiple scenarios and compare the results with several already available designs. The benchmarking results of multiple operating characteristics convincingly support that our design leads in overall performance while ensuring robustness.

Subjects

MeSH terms (MEDLINE)

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDose-Response Relationship, DrugResearch DesignHumansComputer SimulationModels, StatisticalMaximum Tolerated DoseReproducibility of ResultsProbabilityTreatment Outcome

Author keywords

Bayesian quasi likelihooddose optimizationmulti‐grade outcomesoptimal biological dosephase I/II trialsutility

Authors and institutions

  • Department of Statistical and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Mathematics and Statistics, York University, Toronto, Ontario, Canada.
  • School of Data Science, Fudan University, Shanghai, China.

ORCID profiles: Ruitao Lin, Haolun Shi, Xiaolei Lin

Funding

  • National Natural Science Foundation of China
  • Natural Sciences and Engineering Research Council of Canada
  • Canadian Statistical Sciences Institute (CANSSI)

Cite

APA

Yan, Y., Lin, R., Guan, T., Shi, H., & Lin, X. (2025). A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes. Statistics in Medicine. https://doi.org/10.1002/sim.70049

Vancouver

Yan Y, Lin R, Guan T, Shi H, Lin X. A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes. Statistics in Medicine. 2025. doi:10.1002/sim.70049

BibTeX
@article{Yan2025,
  author = {Yan, Yichen and Lin, Ruitao and Guan, Tianyu and Shi, Haolun and Lin, Xiaolei},
  title = {A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70049}
}
Start for free →